Recombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological)

重组人II型肿瘤坏死因子受体-抗体融合蛋白（海正生物）

Report date: 2025/12/23 14:30:09

Base Information

Drug NameRecombinant human type II tumor necrosis factor receptor-antibody fusion protein(Hisun Biological)
Drug Alias Name重组人II型肿瘤坏死因子受体-抗体融合蛋白
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionTumor necrosis factor receptor superfamily member 1B antagonists
TargetsTumor necrosis factor receptor superfamily member 1B
Therapy Area/IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Global Approved IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Approved Indications in ChinaPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Original Approved Country/TerritoryMainland China
Original Approved Date2015/04/09
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHisun Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHisun Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A